Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LA JOLLA PHARMACEUTICAL COLJPC · Entity 124310 | Chief Medical Officer | July 01, 2020 | September 17, 2020 |
| REVELATION BIOSCIENCES, INC.REVB · Entity 8359 | Director | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LA JOLLA PHARMACEUTICAL CO
Report date July 01, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,447 |
Reported balance
After 2020-09-15 transaction · row 1
1 source rowRow 1 · 2020-09-15 · Grant · Acquired 286 · Balance 13,447 F1: These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 · Expires 2030-09-15 | Direct | 286 |
Reported balance
After 2020-09-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-09-15 · Grant · Acquired 286 · Balance 286 F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2030-07-01 | Direct | 60,000 |
Reported balance
After 2020-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-07-01 · Grant · Acquired 60,000 · Balance 60,000 F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years.
REVELATION BIOSCIENCES, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,169 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Grant · Acquired 32,011 · Balance 44,169 F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:00 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 32,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355662 · ownership.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,169 F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 22:30 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | Tax withholdingCommon Stock | 2,261 | $1.85 | $4,182.85 |
DisclosureSEC source: 0001193125-26-039695 · ownership.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,158 F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:01 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 41,981 | $0.90 | $37,782.90 |
DisclosureSEC source: 0001193125-26-010586 · ownership.xml · nonDerivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,667 F1 · security: Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant. Read SEC document |
| October 29, 2025 Filed Oct 31, 2025 17:01 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 15,625 | $1.28 | $20,000.00 |
DisclosureSEC source: 0001193125-25-260426 · ownership.xml · nonDerivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,686 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 23:14 UTC | REVELATION BIOSCIENCES, INC. REVB · Entity 8359 | GrantCommon Stock | 181 | $3.87 | $700.47 |
DisclosureSEC source: 0000950170-25-020126 · ownership.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 181 F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:57 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 286 | $0.00 Strike: $4.53 | $0.00 |
DisclosureSEC source: 0000920465-20-000145 · wf-form4_160037622700031.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286 Underlying: Common Stock · 286 shares Expires 2030-09-15 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:57 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 286 | $3.85 | $1,101.10 |
DisclosureSEC source: 0000920465-20-000145 · wf-form4_160037622700031.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,447 F1 · kind: These shares were acquired on 09/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 550 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000920465-20-000139 · wf-form4_159907782635396.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550 Underlying: Common Stock · 550 shares Expires 2030-08-31 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 31, 2020 Filed Sep 2, 2020 16:17 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 550 | $3.57 | $1,963.50 |
DisclosureSEC source: 0000920465-20-000139 · wf-form4_159907782635396.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,161 F1 · kind: These shares were acquired on 08/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 17:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 589 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0000920465-20-000135 · wf-form4_159778549876939.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 589 Underlying: Common Stock · 589 shares Expires 2030-08-14 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| August 14, 2020 Filed Aug 18, 2020 17:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 589 | $3.34 | $1,967.26 |
DisclosureSEC source: 0000920465-20-000135 · wf-form4_159778549876939.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,611 F1 · kind: These shares were acquired on 08/14/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 581 | $0.00 Strike: $3.98 | $0.00 |
DisclosureSEC source: 0000920465-20-000124 · wf-form4_159657609752618.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 581 Underlying: Common Stock · 581 shares Expires 2030-07-31 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 17:24 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 581 | $3.38 | $1,963.78 |
DisclosureSEC source: 0000920465-20-000124 · wf-form4_159657609752618.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,022 F1 · kind: These shares were acquired on 07/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 521 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0000920465-20-000117 · wf-form4_159501630557712.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521 Underlying: Common Stock · 521 shares Expires 2030-07-15 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 521 | $3.77 | $1,964.17 |
DisclosureSEC source: 0000920465-20-000117 · wf-form4_159501630557712.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,441 F1 · kind: These shares were acquired on 07/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| July 01, 2020 Filed Sep 17, 2020 16:57 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0000920465-20-000145 · wf-form4_160037622700031.xml · derivative · entry 3 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-07-01 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 19:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 543 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0000920465-20-000116 · wf-form4_159364487774313.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543 Underlying: Common Stock · 543 shares Expires 2030-06-30 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 30, 2020 Filed Jul 1, 2020 19:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 543 | $3.62 | $1,965.66 |
DisclosureSEC source: 0000920465-20-000116 · wf-form4_159364487774313.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,920 F1 · kind: These shares were acquired on 06/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 18:26 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantEmployee Stock Option (Right to Buy) · Derivative | 435 | $0.00 Strike: $5.31 | $0.00 |
DisclosureSEC source: 0000920465-20-000088 · wf-form4_159243275533529.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 435 Underlying: Common Stock · 435 shares Expires 2030-06-15 F2 · derivative.exercise_date: The stock options vest and become exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vest and become exercisable ratably on a monthly basis over the next three years. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 18:26 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 435 | $4.51 | $1,961.85 |
DisclosureSEC source: 0000920465-20-000088 · wf-form4_159243275533529.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,377 F1 · kind: These shares were acquired on 06/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 491 | $0.00 Strike: $4.72 | $0.00 |
DisclosureSEC source: 0000920465-20-000082 · wf-form4_159112814556681.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491 Underlying: Common Stock · 491 shares Expires 2030-05-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 491 | $4.01 | $1,968.91 |
DisclosureSEC source: 0000920465-20-000082 · wf-form4_159112814556681.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,942 F1 · kind: These shares were acquired on 05/29/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 335 | $0.00 Strike: $6.89 | $0.00 |
DisclosureSEC source: 0000920465-20-000075 · wf-form4_158991872006850.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335 Underlying: Common Stock · 335 shares Expires 2030-05-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| May 15, 2020 Filed May 19, 2020 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 335 | $5.86 | $1,963.10 |
DisclosureSEC source: 0000920465-20-000075 · wf-form4_158991872006850.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,451 F1 · kind: These shares were acquired on 05/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 30, 2020 Filed May 4, 2020 16:09 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 319 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0000920465-20-000064 · wf-form4_158862293414800.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319 Underlying: Common Stock · 319 shares Expires 2030-04-30 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 30, 2020 Filed May 4, 2020 16:09 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 319 | $6.17 | $1,968.23 |
DisclosureSEC source: 0000920465-20-000064 · wf-form4_158862293414800.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,116 F1 · kind: These shares were acquired on 04/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 350 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0000920465-20-000049 · wf-form4_158715375511570.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350 Underlying: Common Stock · 350 shares Expires 2030-04-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 350 | $5.61 | $1,963.50 |
DisclosureSEC source: 0000920465-20-000049 · wf-form4_158715375511570.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,797 F1 · kind: These shares were acquired on 04/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 18:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 165 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0000920465-20-000047 · wf-form4_158586531717830.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165 Underlying: Common Stock · 165 shares Expires 2030-03-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 31, 2020 Filed Apr 2, 2020 18:08 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 165 | $3.57 | $589.05 |
DisclosureSEC source: 0000920465-20-000047 · wf-form4_158586531717830.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,447 F1 · kind: These shares were acquired on 03/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 173 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0000920465-20-000042 · wf-form4_158438952991408.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173 Underlying: Common Stock · 173 shares Expires 2030-03-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| March 13, 2020 Filed Mar 16, 2020 16:12 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 173 | $3.40 | $588.20 |
DisclosureSEC source: 0000920465-20-000042 · wf-form4_158438952991408.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,282 F1 · kind: These shares were acquired on 03/13/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 102 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0000920465-20-000038 · wf-form4_158327002635563.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102 Underlying: Common Stock · 102 shares Expires 2030-02-28 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 16:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 102 | $5.78 | $589.56 |
DisclosureSEC source: 0000920465-20-000038 · wf-form4_158327002635563.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,109 F1 · kind: These shares were acquired on 02/28/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:48 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 83 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0000920465-20-000033 · wf-form4_158214887057989.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83 Underlying: Common Stock · 83 shares Expires 2030-02-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 16:48 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 83 | $7.14 | $592.62 |
DisclosureSEC source: 0000920465-20-000033 · wf-form4_158214887057989.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,007 F1 · kind: These shares were acquired on 02/14/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 101 | $0.00 Strike: $6.85 | $0.00 |
DisclosureSEC source: 0000920465-20-000027 · wf-form4_158085011745350.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101 Underlying: Common Stock · 101 shares Expires 2030-01-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 31, 2020 Filed Feb 4, 2020 16:02 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 101 | $5.82 | $587.82 |
DisclosureSEC source: 0000920465-20-000027 · wf-form4_158085011745350.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,924 F1 · kind: These shares were acquired on 01/31/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 498 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0000920465-20-000023 · wf-form4_157929563318358.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 498 Underlying: Common Stock · 498 shares Expires 2030-01-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 16:14 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 498 | $6.70 | $3,336.60 |
DisclosureSEC source: 0000920465-20-000023 · wf-form4_157929563318358.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,823 F1 · kind: These shares were acquired on 01/15/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 09, 2020 Filed Jan 13, 2020 16:18 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $5.25 | $0.00 |
DisclosureSEC source: 0000920465-20-000014 · wf-form4_157895027531774.xml · derivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-01-09 F1 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:34 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 172 | $0.00 Strike: $3.93 | $0.00 |
DisclosureSEC source: 0000920465-20-000004 · wf-form4_157808727192632.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172 Underlying: Common Stock · 172 shares Expires 2029-12-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 16:34 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 172 | $3.34 | $574.48 |
DisclosureSEC source: 0000920465-20-000004 · wf-form4_157808727192632.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,325 F1 · kind: These shares were acquired on 12/31/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 201 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000920465-19-000173 · wf-form4_157661657252922.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201 Underlying: Common Stock · 201 shares Expires 2029-12-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 16:03 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 201 | $2.85 | $572.85 |
DisclosureSEC source: 0000920465-19-000173 · wf-form4_157661657252922.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,153 F1 · kind: These shares were acquired on 12/13/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 16:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 247 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0000920465-19-000169 · wf-form4_157540847048274.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247 Underlying: Common Stock · 247 shares Expires 2029-11-29 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 29, 2019 Filed Dec 3, 2019 16:28 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 247 | $2.33 | $575.51 |
DisclosureSEC source: 0000920465-19-000169 · wf-form4_157540847048274.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,952 F1 · kind: These shares were acquired on 11/29/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 111 | $0.00 Strike: $6.02 | $0.00 |
DisclosureSEC source: 0000920465-19-000161 · wf-form4_157419788004975.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111 Underlying: Common Stock · 111 shares Expires 2029-11-15 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 16:11 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantCommon Stock | 111 | $5.12 | $568.32 |
DisclosureSEC source: 0000920465-19-000161 · wf-form4_157419788004975.xml · nonDerivative · entry 1 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,705 F1 · kind: These shares were acquired on 11/15/2019 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| October 31, 2019 Filed Nov 5, 2019 16:05 UTC | LA JOLLA PHARMACEUTICAL CO LJPC · Entity 124310 | GrantStock Option (Right to Buy) · Derivative | 96 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0000920465-19-000151 · wf-form4_157298790491069.xml · derivative · entry 2 Chawla Lakhmir S · CIK 0001646626 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96 Underlying: Common Stock · 96 shares Expires 2029-10-31 F2 · derivative.exercise_date: The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.